Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer.
Clin Chim Acta
; 413(13-14): 1121-6, 2012 Jul 11.
Article
em En
| MEDLINE
| ID: mdl-22465234
ABSTRACT
BACKGROUND:
The role of matrix metalloproteinase 9 (MMP-9) expression in non-small cell lung cancer (NSCLC) remains controversial. We performed a systematic review of the literature with meta-analysis.METHODS:
Electronic databases were used to identify published studies before December 1, 2011. Pooled hazard ratio (HR) with 95% confidence interval (95% CI) was used to estimate the strength of the association between MMP-9 expression survival of NSCLC patients. Heterogeneity and publication bias were also assessed.RESULTS:
The final analysis of 2029 NSCLC cases from 17 studies is presented. The combined HR of 1.84 (95% CI 1.62-2.09) suggested that MMP-9 over-expression had a poor prognosis in patients with NSCLC. Subgroup analyses also detected significant association. Heterogeneity and publication bias was absent in current meta-analysis. Sensitivity analyses suggested that the summary statistics obtained should approximate the actual average.CONCLUSION:
High MMP-9 expression is associated with a poor prognosis in patients with NSCLC.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Regulação Neoplásica da Expressão Gênica
/
Carcinoma Pulmonar de Células não Pequenas
/
Metaloproteinase 9 da Matriz
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Clin Chim Acta
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
China